Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Metastatic GEP-NEC
NCT03147404Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in neuroendocrine carcinoma (NEC), sponsored by Samsung Medical Center. Started Dec 2017; status: completed.
02
Drugs
avelumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03147404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147404.